Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 22306906)

1.

Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.

Holt DM, Ma X, Kundu N, Collin PD, Fulton AM.

J Immunother. 2012 Feb-Mar;35(2):179-88. doi: 10.1097/CJI.0b013e318247a5e9.

2.

Response to tumor necrosis factor-α mediated inflammation involving activation of prostaglandin E2 and Wnt signaling in nucleus pulposus cells.

Hiyama A, Yokoyama K, Nukaga T, Sakai D, Mochida J.

J Orthop Res. 2015 Jun 29. doi: 10.1002/jor.22959. [Epub ahead of print]

PMID:
26123748
3.

Prostaglandin E2 blockade enhances the pulmonary anti-Cryptococcus neoformans immune reaction via the induction of TLR-4.

Shen L, Liu Y.

Int Immunopharmacol. 2015 Jun 26. pii: S1567-5769(15)00325-2. doi: 10.1016/j.intimp.2015.06.026. [Epub ahead of print]

PMID:
26122137
4.

Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors.

Nasrallah R, Hassouneh R, Zimpelmann J, Karam AJ, Thibodeau JF, Burger D, Burns KD, Kennedy CR, Hébert RL.

Lab Invest. 2015 Jun 29. doi: 10.1038/labinvest.2015.79. [Epub ahead of print]

PMID:
26121313
5.

Discovery and characterization of a potent and selective EP4 receptor antagonist.

Schiffler MA, Chandrasekhar S, Fisher MJ, Harvey A, Kuklish SL, Wang XS, Warshawsky AM, York JS, Yu XP.

Bioorg Med Chem Lett. 2015 Jun 4. pii: S0960-894X(15)00574-0. doi: 10.1016/j.bmcl.2015.05.091. [Epub ahead of print]

PMID:
26091726
6.

miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).

Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Krylov SN, Fokas E, Boutros PC, Liu SK.

Oncotarget. 2015 Jun 4. [Epub ahead of print]

7.

A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques.

Fox BM, Beck HP, Roveto PM, Kayser F, Cheng Q, Dou H, Williamson T, Treanor J, Liu H, Jin L, Xu G, Ma J, Wang S, Olson SH.

J Med Chem. 2015 Jun 24. [Epub ahead of print]

PMID:
26061158
8.

Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors.

Sreeramkumar V, Hons M, Punzón C, Stein JV, Sancho D, Fresno M, Cuesta N.

Immunol Cell Biol. 2015 Jun 8. doi: 10.1038/icb.2015.62. [Epub ahead of print]

PMID:
26051593
9.

Impaired EP2 Expression Causes Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with AERD.

Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, Byun HM, Bhattacharyya N, Steinke JW, Boyce JA, Laidlaw TM.

Am J Respir Cell Mol Biol. 2015 Jun 6. [Epub ahead of print]

PMID:
26051534
10.

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.

Müller C, Tufa DM, Chatterjee D, Mühlradt PF, Schmidt RE, Jacobs R.

Cancer Immunol Immunother. 2015 Jun 3. [Epub ahead of print]

PMID:
26036909
11.

Natural products with therapeutic potential in melanoma metastasis.

AlQathama A, Prieto JM.

Nat Prod Rep. 2015 May 27. [Epub ahead of print]

PMID:
26018751
12.

Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype.

Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, Belvisi MG.

Thorax. 2015 May 4. pii: thoraxjnl-2014-206592. doi: 10.1136/thoraxjnl-2014-206592. [Epub ahead of print]

13.

Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.

Parida S, Parekh A, Dey G, Ghosh SC, Mandal M.

Cancer Biol Ther. 2015 Jun 3;16(6):922-32. doi: 10.1080/15384047.2015.1040953. Epub 2015 Apr 20.

PMID:
25894216
14.

MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.

Olesch C, Sha W, Angioni C, Sha LK, Açaf E, Patrignani P, Jakobsson PJ, Radeke HH, Grösch S, Geisslinger G, von Knethen A, Weigert A, Brüne B.

Oncotarget. 2015 Apr 30;6(12):10284-96.

15.

Antitumor immunostimulatory activity of polysaccharides from Salvia chinensis Benth.

Shu G, Zhao W, Yue L, Su H, Xiang M.

J Ethnopharmacol. 2015 Jun 20;168:237-47. doi: 10.1016/j.jep.2015.03.065. Epub 2015 Apr 6.

PMID:
25858511
16.

Selective inhibition of prostaglandin E2 receptors EP2 and EP4 modulates DNA methylation and histone modification machinery proteins in human endometriotic cells.

Arosh JA, Lee J, Starzinski-Powitz A, Banu SK.

Mol Cell Endocrinol. 2015 Jul 5;409:51-8. doi: 10.1016/j.mce.2015.03.023. Epub 2015 Apr 2.

PMID:
25843056
17.

Sequence analysis and identification of new isoform of EP4 receptors in different atlantic salmon tissues (Salmo salar L.) and its role in PGE2 induced immunomodulation in vitro.

Guo TC, Gamil AA, Koenig M, Evensen Ø.

PLoS One. 2015 Apr 2;10(3):e0120483. doi: 10.1371/journal.pone.0120483. eCollection 2015.

18.

Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation.

Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, Brotto M.

Cell Cycle. 2015 May 19;14(10):1507-16. doi: 10.1080/15384101.2015.1026520.

PMID:
25785867
19.

Newly stemming functions of macula densa-derived prostanoids.

Peti-Peterdi J.

Hypertension. 2015 May;65(5):987-8. doi: 10.1161/HYPERTENSIONAHA.115.04739. Epub 2015 Mar 16. No abstract available.

PMID:
25776068
20.

COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.

Majumder M, Landman E, Liu L, Hess D, Lala PK.

Mol Cancer Res. 2015 Jun;13(6):1022-33. doi: 10.1158/1541-7786.MCR-14-0543. Epub 2015 Mar 2.

PMID:
25733698
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk